Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bank of Nova Scotia — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.7 (market cap $29.60B), while Bank of Nova Scotia trades at $90.16 (market cap $108.32B). The key difference: Bank of Nova Scotia is far larger — about 3.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Bank of Nova Scotia pays a 3.64% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BNS | |
|---|---|---|
Market Cap | $29.60B | $108.32B |
Sector | Health | Financials |
52-Week High | $491.22 | $90.29 |
52-Week Low | $205.48 | $56.41 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Bank of Nova Scotia (BNS) trades at $89.92, up 1.54% with a bullish technical outlook supported by moving averages. The company demonstrates consistent earnings growth, beating estimates for three consecutive quarters with Q2 2026 expected at $1.53 EPS. Recent acquisition of MapleMark Bank and dividend increase to $1.14 highlight strategic growth initiatives. Valuation metrics show a P/E of 17.1 and P/B of 1.96, while maintaining strong profitability with 24.86% net income margin.
BNS presents a favorable investment case with analyst consensus leaning bullish (53% buy ratings) and technical indicators supporting upward momentum. Key opportunities include dividend growth, international expansion, and improving ROE at 11.87%. Risks include macroeconomic sensitivity, declining profit margins from 31.47% in 2022 to 20.99% in 2025, and elevated debt levels with $194.31 billion long-term obligations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
